All stories

1 outlets · filed 10 November 2026

Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

This story is from the archive. It was covered between 10 November 2026 and 10 November 2026, and nothing below has been updated since. See what is happening now.

The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.

What the coverage shows

All five outlets focus on the FDA’s warning about GLP-1 drugs and a rare eye condition tied to vision loss, and all say the agency is acting on warning labels or patient information. The Guardian US and BBC foreground blindness or vision loss more directly in their headlines, while Ars Technica is alone in stressing that the risk appears small and the data are mixed. CNBC and ABC frame it as a potential increased risk, with ABC naming several drugs and saying the warning is new.

Written by Crossfiled from the 1 headlines and extracts below, not from the articles themselves. It describes how the outlets framed this, not what happened. Open any headline for a summary of that article.

BBC News

How it broke

In this story

1outlets
0videos
1articles

More on Health

Every Health story, across every outlet